Opioid Use Down with Erector Spinae Plane Blocks in Lumbar Laminectomy

Earlier Onset of A-Fib Linked to Risk of Developing All-Cause Dementia
November 9, 2023
FDA Approves Ixchiq (Chikungunya Vaccine, Live) for the Prevention of Disease caused by Chikungunya Virus
November 10, 2023
Earlier Onset of A-Fib Linked to Risk of Developing All-Cause Dementia
November 9, 2023
FDA Approves Ixchiq (Chikungunya Vaccine, Live) for the Prevention of Disease caused by Chikungunya Virus
November 10, 2023

Medically reviewed by Carmen Pope, BPharm.
By Elana Gotkine HealthDay Reporter

November 9, 2023 - For patients undergoing open lumbar laminectomy, ultrasound-guided bilateral erector spinae plane blocks (ESPBs) combined with multimodal analgesia reduce opioid consumption, according to a study recently published in the European Spine Journal.

Jesse W. Stewart, M.D., from UT Southwestern Medical Center in Dallas, and colleagues compared the analgesic effects of preoperative, bilateral, ultrasound-guided ESPBs combined with standardized multimodal analgesia with multimodal analgesia alone (25 patients in each group) among patients undergoing one or two level open lumbar laminectomy.

The researchers found that with ESPBs, opioid requirements at 24 hours were significantly lower (31.9 ± 12.3 versus 61.2 ± 29.9 mg oral opioid equivalents). In the post-anesthesia care unit (PACU) and through postoperative day two, pain scores were significantly lower with ESPBs. Fewer patients in the ESPB group versus the non-ESPB group received postoperative antiemetic therapy (12 versus 48 percent). In addition, significantly shorter PACU duration was seen with ESPBs (49.7 ± 9.5 versus 79.9 ± 24.6 minutes).

"These findings suggest that ESPBs can play a major role in an opioid-sparing recovery plan that utilizes a multimodal pain management approach, not only in spine surgery but potentially for other types of surgery as well," Stewart said in a statement.

Actual drug patent expiration dates and availability of new medications are subject to change due to patent litigation, settlement agreements, additional patents, exclusivities, and final FDA approval. Distribution and availability of new medications at pharmacies may not occur immediately following FDA approval. Patients are advised to speak with their healthcare professional or pharmacist regarding appropriateness as well as actual availability.

*This is provided for information only. The reference to any medication above does not mean the medication is covered by your plan.